JP2010522774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522774A5 JP2010522774A5 JP2010501409A JP2010501409A JP2010522774A5 JP 2010522774 A5 JP2010522774 A5 JP 2010522774A5 JP 2010501409 A JP2010501409 A JP 2010501409A JP 2010501409 A JP2010501409 A JP 2010501409A JP 2010522774 A5 JP2010522774 A5 JP 2010522774A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- compound
- combination according
- angiogenic
- calcineurin inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 8
- 230000001772 anti-angiogenic Effects 0.000 claims 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 4
- 108010036949 Cyclosporine Proteins 0.000 claims 4
- 229960001265 ciclosporin Drugs 0.000 claims 4
- 102100009787 CABIN1 Human genes 0.000 claims 3
- 108010066057 CABIN1 Proteins 0.000 claims 3
- 229940119017 Cyclosporine Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 230000001506 immunosuppresive Effects 0.000 claims 2
- 210000004204 Blood Vessels Anatomy 0.000 claims 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 229960002800 prednisolone acetate Drugs 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Claims (13)
- 治療上有効な量の（ｉ）少なくとも１つの抗血管形成化合物と（ｉｉ）少なくとも１つのコルチコステロイドとを含んでなる、組み合わせ物。
- 前記抗血管形成化合物が、免疫抑制化合物である、請求項１に記載の組み合わせ物。
- 前記免疫抑制化合物が、カルシニュリン阻害剤およびｍＴＯＲ阻害剤からなる群から選択される、請求項２に記載の組み合わせ物。
- 前記抗血管形成化合物が、ＶＥＧＦを阻害する化合物である、請求項１に記載の組み合わせ物。
- 前記カルシニュリン阻害剤が、シクロスポリンである、請求項３に記載の組み合わせ物。
- 前記カルシニュリン阻害剤が、シクロスポリンＡである、請求項３に記載の組み合わせ物。
- 眼科的に適合する溶媒成分をさらに含んでなる、請求項１〜６のいずれか一項に記載の組み合わせ物。
- 前記抗血管形成化合物が、約１０％以下の量で存在する、請求項１に記載の組み合わせ物。
- 前記抗血管形成化合物がシクロスポリンＡであり、その濃度が約０．００１％〜約０．０５％間である、請求項１に記載の組み合わせ物。
- 前記コルチコステロイドが約０．０１％〜約４％の量で存在する、請求項１に記載の組み合わせ物。
- ０．０１２％の酢酸プレドニゾロンと０．０５％のシクロスポリンを含む、請求項１に記載の組み合わせ物。
- 同時もしくは連続投与、または経時的交互投与のための、請求項１〜１１のいずれか一項に記載の組み合わせ物。
- 血管形成媒介性の眼科的疾患または病気の治療に用いるための、請求項１〜１２のいずれか一項に記載の組み合わせ物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07360012 | 2007-03-30 | ||
| PCT/EP2008/002426 WO2008119500A1 (en) | 2007-03-30 | 2008-03-27 | Methods for treating neovascular ocular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522774A JP2010522774A (ja) | 2010-07-08 |
| JP2010522774A5 true JP2010522774A5 (ja) | 2011-05-19 |
Family
ID=39564402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501409A Pending JP2010522774A (ja) | 2007-03-30 | 2008-03-27 | 血管新生眼疾患を治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100233194A1 (ja) |
| EP (1) | EP2139492A1 (ja) |
| JP (1) | JP2010522774A (ja) |
| CN (1) | CN101678034A (ja) |
| AU (1) | AU2008234141A1 (ja) |
| CA (1) | CA2681361A1 (ja) |
| WO (1) | WO2008119500A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722015B2 (en) * | 2010-04-01 | 2014-05-13 | The Schepens Eye Research Institute, Inc. | Compositions and methods for treatment of angiogenesis-associated ocular disorders |
| WO2011161295A2 (es) * | 2010-06-23 | 2011-12-29 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de compuestos anticalcineurina para el tratamiento de patologías que cursan con neovascularización ocular |
| MA41818A (fr) * | 2015-03-27 | 2018-01-30 | Leo Pharma As | Timbre à micro-aiguilles pour administration d'un principe actif à la peau |
| WO2018093797A1 (en) * | 2016-11-15 | 2018-05-24 | The Schepens Eye Research Institute, Inc. | Compositions and methods for the treatment of aberrant angiogenesis |
| EP3639854A4 (en) | 2017-06-16 | 2021-03-03 | The Doshisha | MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF |
| WO2019099560A1 (en) | 2017-11-14 | 2019-05-23 | The Schepens Eye Research Institute, Inc. | Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
| WO2020081941A1 (en) * | 2018-10-19 | 2020-04-23 | Medicinova, Inc. | Methods of treating ophthalmic disease/disorder or injury with ibudilast |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| TR200302105T4 (tr) * | 2000-04-07 | 2004-02-23 | Laboratoire Medidom S. A. | Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları. |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| WO2006039558A2 (en) | 2004-10-09 | 2006-04-13 | Formurex, Inc. | Ocular agent delivery systems |
| US20060148686A1 (en) * | 2004-12-30 | 2006-07-06 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy |
| AU2006270041B2 (en) | 2005-07-18 | 2011-08-18 | Minu, Llc | Enhanced ocular neuroprotection/neurostimulation |
| US20070087962A1 (en) * | 2005-10-17 | 2007-04-19 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| DE102006051512A1 (de) * | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
-
2008
- 2008-03-27 JP JP2010501409A patent/JP2010522774A/ja active Pending
- 2008-03-27 AU AU2008234141A patent/AU2008234141A1/en not_active Abandoned
- 2008-03-27 EP EP08716704A patent/EP2139492A1/en not_active Withdrawn
- 2008-03-27 CA CA002681361A patent/CA2681361A1/en not_active Abandoned
- 2008-03-27 WO PCT/EP2008/002426 patent/WO2008119500A1/en active Application Filing
- 2008-03-27 US US12/593,758 patent/US20100233194A1/en not_active Abandoned
- 2008-03-27 CN CN200880010884A patent/CN101678034A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522774A5 (ja) | ||
| Weir et al. | Assessment and management of hypertension in transplant patients | |
| Mentz et al. | The past, present and future of renin–angiotensin aldosterone system inhibition | |
| Ruggenenti et al. | The RAAS in the pathogenesis and treatment of diabetic nephropathy | |
| Seeland et al. | Sex and gender differences in cardiovascular drug therapy | |
| Graziani et al. | Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis | |
| JP2017503820A5 (ja) | ||
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| Vivarelli et al. | Sirolimus in liver transplant recipients: a large single-center experience | |
| Li et al. | Tacrolimus therapy in adults with steroid-and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR | |
| JP2021523103A (ja) | Ｉｌ−３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用 | |
| Goldsmith et al. | Intestinal epithelial cell–derived μ-opioid signaling protects against ischemia reperfusion injury through PI3K Signaling | |
| JP2015057436A5 (ja) | ||
| JP2016538270A5 (ja) | ||
| Kühnast et al. | Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE* 3Leiden. CETP transgenic mice with or without treatment with atorvastatin | |
| JP2010514834A5 (ja) | ||
| JP2018504436A5 (ja) | ||
| Liu et al. | Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial | |
| Naumovic et al. | Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study | |
| Drew | Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections | |
| JP2013028611A5 (ja) | ||
| JP2017513809A5 (ja) | ||
| Martin-Ventura et al. | Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis: New strategies to prevent cardiovascular risk in chronic kidney disease | |
| JP2019507785A5 (ja) | ||
| Codina et al. | Chronic kidney allograft disease: new concepts and opportunities |